INMB INmune Bio Inc.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.

Date	Price Target	Rating	Analyst
1/28/2025	$23.00	Buy	Rodman & Renshaw
10/21/2024	$20.00	Buy	Alliance Global Partners
9/27/2024	$18.00	Outperform	Raymond James
8/22/2024	$22.00	Sector Outperform	Scotiabank
6/1/2023	$16.00	Outperform	Robert W. Baird
5/24/2022	$14.00 → $7.00	Buy → Neutral	B. Riley Securities
1/24/2022	$32.00 → $20.00	Buy	B. Riley Securities
7/7/2021	$32.00 → $42.00	Buy	Maxim Group

INmune Bio Inc.

Peers

Recent Analyst Ratings for INmune Bio Inc.

INmune Bio Inc. SEC Filings

SEC Form S-8 filed by INmune Bio Inc.

SEC Form S-8 filed by INmune Bio Inc.

INmune Bio Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEFR14A filed by INmune Bio Inc.

INmune Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by INmune Bio Inc.

INmune Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by INmune Bio Inc.

INmune Bio Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Ganjei James Kelly

SEC Form 4 filed by Director Juda Scott

SEC Form 4 filed by Director Allen Marcia

SEC Form 4 filed by Chief Scientific Officer Lowdell Mark William

SEC Form 4 filed by Director Schroeder Timothy J

SEC Form 4 filed by Chief Financial Officer Moss David J

SEC Form 4 filed by President and CEO Tesi Raymond Joseph

Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)